CoreAge Rx vs Peter MD
Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Peter MD head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 76 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
That doesn't make Peter MD a bad call — it's best for readers who want glp-1 care bundled with trt, sermorelin, nad+ or hair-loss treatment on a single account, and are comfortable reading a tiered price ladder rather than one flat monthly figure this site can map straight onto a dose. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Peter MD | |
|---|---|---|
| Brief Score | 94/100 (A) | 76/100 (C) |
| Semaglutide | $149/mo | $149/mo new-user tier · $139/mo returning-user tier (GLP1 + B12) |
| Tirzepatide | $349/mo | $249/mo after a $149 first month (billed quarterly, 60mg) |
| Coverage | All 50 states | Most states — exclusions vary by treatment (not a single list) |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.
Peter MD: First reading, 2026-08-04: tirzepatide runs $149 the first month before resetting to $249 on quarterly billing; compounded semaglutide (sold as GLP1 + B12) splits into a $149/mo new-user tier and a $139/mo returning-user tier rather than one flat monthly rate.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.